Professional indemnity insurance for APNA members to 31 March 2019 for $9.17 per month
Seqirus, a CSL company, is a leading provider of essential vaccines and pharmaceuticals. We have served Australia’s healthcare needs for over a century and today we develop, manufacture and source medicines that support the health and wellbeing of many thousands of people around the world. Seqirus operates Australia’s only local manufacturing facility for seasonal and pandemic influenza vaccine and produces a range of unique medicines in the National Interest including antivenoms and Q fever vaccine. Seqirus also in-licenses a broad range of paediatric and adult vaccines and specialty pharmaceutical products.
Community Immunity is an online immunisation toolkit proudly provided by Seqirus™ and designed for you as a nurse in primary health care to maximise adult immunisation in your clinic. Over 2200 nurses have now registered on the Community Immunity website www.communityimmunity.com.au
Visit the Seqirus stand to see the latest tools and resources available on the Community Immunity website.
GSK is a global research-based pharmaceutical and healthcare company with a mission to improve the quality of human life.
Our vaccines business is one of the largest in the world. We produce paediatric and adult vaccines for a range of infectious diseases.
In Australia our vaccines portfolio helps prevent illnesses such as hepatitis, rotavirus and HPV infections, diphtheria, tetanus, whooping cough, measles, mumps, rubella, bacterial meningitis and influenza.
We are the primary supplier of childhood vaccines to the National Immunisation Program (NIP) in Australia, providing protection against potentially life threatening diseases like polio, measles, mumps and rubella to nearly 4 million children each year.
The program provides access to tools and educational resources for healthcare professionals supported by an Osteoporosis Nurse Educator. There is also the opportunity to participate in an accredited clinical audit.
Find more information on the website: www.reframeosteoporosis.com.au
The Australian Digital Health Agency was established in July 2016 to improve health outcomes for all Australians through best use and design of digital services. It is responsible for national systems – including My Health Record – and for implementing Australia’s National Digital Health Strategy in collaboration with partners across the community.
The Strategy will help put consumers at the centre of their health and care and empower more choice, control and transparency. By the end of 2018, all Australians will have a My Health Record, which contains a secure mobile summary of their health information that can be shared with care professionals – unless they choose to opt out.
Visit our website for more information.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.
We have more than 60 years’ history in Australia and employ around 800 associates across our three divisions. We believe continued R&D is essential to innovation and in Australia we invest around 20M annually in local clinical trials.
Our mission is to discover new ways to improve and extend people’s lives. We are committed to patients, associates, healthcare partners and society at large to improve access to healthcare and essential medicines as we aspire to become a trusted leader in changing the practice of medicine.
To find out more about Novartis in Australia visit www.novartis.com.au
Bio to come..
Nestlé Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. We aim to pioneer the development and application of evolving science to create a new role for nutrition in disease prevention and management.
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For 40 years, the Accu-Chek brand has been dedicated to enable people with diabetes to live life as normal and active as possible as well as to empower healthcare professionals manage their patients’ condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management. It encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome.
For more information: www.accu-chek.com.
Bio to come...
The National Cervical Screening Program (NCSP) is changing. These sessions will outline the key aspects of these changes which include; replacement of the two yearly Pap test with a five yearly Cervical Screening Test; commencement age will increase to 25 years and the exit age to 74; management of test results will also alter. Find out more here
Diabetes Queensland is a charity and member-based organisation that serves as the peak body for people with diabetes in Queensland - providing a single, powerful and collective voice for the diabetes community. As the state based agent for the National Diabetes Services Scheme (NDSS) Diabetes Queensland offers a variety of resources and education programs to assist health professionals in their treatment and management of people with diabetes. To find out more, contact us on our Helpline – 1300 136 588 or visit www.diabetesqld.org.au
The Nursing in Primary Health Care Program aims to support nurses in primary health care by: improving employment opportunities, recruitment and retention; identifying sustainable and innovative models of care; and ensuring nurses have the knowledge and skills to deliver best practice clinical services.
Four main projects make up the NiPHC Program of work:
Transition to Practice Pilot Program
The Transition to Practice Pilot (TPPP) program is a structured 12-month transition program, which aims to increase the confidence, skills and knowledge of newly graduated and existing nurses starting work in primary health care settings.
For more information visit apna.asn.au/nursing-tools/transitiontopractice
Career and Education Frameworks for Nurses in Primary Health Care
The Career and Education Framework delivers resources and a practical toolkit (MyNursingFuture.com.au), which supports career and education progression for nurses in primary health care. The project aims to improve employment opportunities, recruitment and retention of nurses in primary health care.
Enhanced Nurse Clinics
The Enhanced Nurse Clinics project supported the establishment of 11 nurse clinics, Australia-wide. With an extensive evaluation of the nurse clinics, the project outcomes include recommendations, resources, and tools, designed to support primary health care organisations to commence their own nurse clinic models. To access the Nurse Clinic resources visit apna.asn.au/nursing-tools/nurse-clinics
Chronic Disease Management for nurses in primary health care
This project delivers face-to-face workshops on chronic disease management for nurses working in primary health care across Australia. For details of upcoming events visit apna.asn.au/education/cdmha
The Nursing in Primary Health Care (NiPHC) Program is funded by the Australian Government Department of Health from 2015 to 2018.
Bio to come...
Palliative Care Australia is the national peak body for palliative care, providing leadership on palliative care policy and community engagement. It aims to improve the quality of life and death for people with a life-limiting illness, their families and carers.
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur produces a portfolio of high quality vaccines that matches its areas of expertise and meets public-health demand. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development.
Working Together for a Healthier World®
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.
We strive to set the standard for quality, safety and value in the discovery, development and manufacturing
of medicines. Our diversified global health care portfolio includes human biologic and small molecule
medicines and vaccines, as well as many of the world’s best-known consumer products.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our
responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care
providers, governments and local communities to support and expand access to reliable, affordable health
care around the world.
For more than 150 years, Pfizer has worked to make a difference for all who rely on us. Visit the website for more information: www.pfizer.com.au